Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11)
Based on 2 publication(s) in Google Scholar
Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) is a rat-derived IgG1 antibody inhibitor, targeting to TNF-alpha/TNFSF2. Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) neutralizes of TNF-alpha. Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) can be used for the researches of cancer, infection and immunology, such as dengue virus and B16K1 tumor.
For research use only. We do not sell to patients.
- Purity : 98.19%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11)
More
Biological Activity
Description
Isotype
Rat IgG1
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
TNF-alpha/TNFSF2
In Vitro
Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) neutralizes endotoxin-induced murine embryo fibroblasts TNF production[3].
Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) (10-1000 ng/mL, 7 days) reduces the number of differentiated osteoclasts in RAW264.7 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) (100 μg, i.p., at days 1, 2, 3) decreases dengue virus 2-induced lethality in mice born to zika virus-immune mothers[2].
Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) (10 mg/kg, i.p., at days 6, 10, 13, 16) inhibits tumor growth and overcomes resistance to anti-PD-1 in B16K1 tumor mice models[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Delta P80 virus-infected mice models[1]
-
Dosage:10 μg
-
Administration:Intravenously injection, a single dose
-
Result:Significantly reduced pulmonary TNF-α levels and improved survival.
-
Animal Model:Mice born to Zika virus-immune mothers[2]
-
Dosage:100 μg
-
Administration:Intraperitoneally injection, at days 1, 2, 3
-
Result:Exhibited improved clinical scores, weight gain, and increased survival.
-
Animal Model:B16K1 tumor mice models[5]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneally injection, at days 6, 10, 13, 16
-
Result:Delayed the B16K1 tumor growth and animal death.
Enhanced anti-PD-1 response.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
in vivo TNFα neutralization; in vitro TNFα neutralization; Western blot
Verified Bioactivity
-
-ELISA.jpg)
Immobilized TNF-alpha/TNFSF2 Protein, Mouse (HY-P7090) can bind Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11). The ED50 for this effect is 9.476 ng/mL. -
Loaded Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) on CM5 biosensor, can bind TNF-alpha/TNFSF2 Protein, Mouse (HY-P7090) with an affinity constant of 8.40E-08 M as determined in SPR assay.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Brain Behav Immun
Systemic inflammation and dorsolateral striatal activity converge to drive repetitive and compulsive-like behaviors caused by chronic stress. [Abstract]2026 Mar 3:106525. PMID: 41786001 -
Int Immunopharmacol
Early P2X7 receptor activation mitigates neonatal group B Streptococcus infection severity and long-term neurodevelopmental impairment. [Abstract]2026 Feb 15:171:116113. PMID: 41475282
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kobayashi M, et al. TNF-α exacerbates SARS-CoV-2 infection by stimulating CXCL1 production from macrophages. PLoS Pathog. 2024 Dec 9;20(12):e1012776. [Content Brief]
[2]. Fowler AM, T et al. Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice. Cell Host Microbe. 2018 Nov 14;24(5):743-750.e5. [Content Brief]
[3]. Havell EA, et al. Endotoxin-induced tumor necrosis factor alpha synthesis in murine embryo fibroblasts. Infect Immun. 1993 May;61(5):1630-5. [Content Brief]
[4]. Katsumata K, et al. Conferring extracellular matrix affinity enhances local therapeutic efficacy of anti-TNF-α antibody in a murine model of rheumatoid arthritis. Arthritis Res Ther. 2019 Dec 23;21(1):298. [Content Brief]
[5]. Bertrand F, et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017 Dec 22;8(1):2256. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) Related Classifications
HY-P990794 Related Classifications
Powered by Bioz